The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
Michael Alexander Gordon
No relevant relationships to disclose
Holly Gundacker
No relevant relationships to disclose
Jacqueline Benedetti
No relevant relationships to disclose
John S. Macdonald
No relevant relationships to disclose
Joaquina Celebre Baranda
Consultant or Advisory Role - Novartis
Research Funding - Genentech; Novartis; Roche/Genentech
Wendy J. Levin
Employment or Leadership Position - Pfizer
C. D. Blanke
No relevant relationships to disclose
Wafaa Elatre
No relevant relationships to disclose
Peggy Weng
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose
Michael F. Press
Consultant or Advisory Role - Abbott Molecular (U); Genentech (U); GlaxoSmithKline (U); Pfizer (U)
Honoraria - Ventana Medical Systems
Research Funding - Ventana Medical Systems